Kadcyla.com
- Title
- KADCYLA® for previously treated HER2+ Metastatic Breast Cancer
- Meta Description
- Learn about KADCYLA® (ado-trastuzumab emtansine), a treatment option for HER2-positive breast cancer. Who is KADCYLA for? KADCYLA is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body. Important Safety Information What is the most important safety information I should know about KADCYLA? KADCYLA is not the same medicine as trastuzumab (Herceptin). Liver problems • KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching Heart problems • KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and ...
- Meta Keywords
- Technologies in use
- reCaptcha, jQuery, Font Awesome